Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.

@article{Hook2008InhibitorsOC,
  title={Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.},
  author={Vivian Hook and Mark Kindy and Gregory R Hook},
  journal={The Journal of biological chemistry},
  year={2008},
  volume={283 12},
  pages={7745-53}
}
Elucidation of Abeta-lowering agents that inhibit processing of the wild-type (WT) beta-secretase amyloid precursor protein (APP) site, present in most Alzheimer disease (AD) patients, is a logical approach for improving memory deficit in AD. The cysteine protease inhibitors CA074Me and E64d were selected by inhibition of beta-secretase activity in regulated secretory vesicles that produce beta-amyloid (Abeta). The regulated secretory vesicle activity, represented by cathepsin B, selectively… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

References

Publications referenced by this paper.
Showing 1-2 of 2 references

Cathepsin B Inhibitors for Alzheimer Disease

X. P. Shi, E. Chen, +12 authors S. J. Gardell
J. Biol. Chem. 276, • 2001

Proteolytic Enzymes: A Practical Approach

R. Beynon, J. Bond
2001

Similar Papers

Loading similar papers…